Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Martek

This article was originally published in The Tan Sheet

Executive Summary

President Steve Dubin will succeed Henry "Pete" Linsert as CEO of Martek June 30 upon Linsert's retirement, the firm announces during a Dec. 13 earnings call. Linsert has served as CEO since 1989; Dubin has held a variety of positions including general counsel and CFO since 1992. Fourth-quarter revenue slipped 6% to $56 mil. compared to the fourth quarter of 2004, Martek reported, with income before taxes down 2% at $7.7 mil. Profit margin on product sales increased to 43% during the quarter due to DHA productivity improvements. Full-year sales grew 18% to roughly $218 mil. The firm expects improved Martek DHA, which launched in November, to lower manufacturing costs and to open new markets due to "enhanced food formulation capabilities"...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel